1/17/2008

Zevalin, an investigational radioimmunotherapy, combined with autologous stem cell transplantation and high-dose chemotherapy, had a 70% progression-free survival rate at two years in a Phase 2 study of non-Hodgkin's lymphoma patients who were ineligible for total-body irradiation, Cell Therapeutics announced. The study results will appear in the Journal of Clinical Oncology.

Full Story:
RTT News

Related Summaries